Pfizer-branded beaker filled with blue liquid in a bright, modern laboratory. Key Points The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October. As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend. Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-st ...